Geron Targets Germany Launch and Deals as RYTELO Sales Grow
What Investors Got Wrong About Geron Before The Drop
Geron: 3 Key Takeaways for Long-Term Investors
Geron Corp (GERN) Q3 2026 Earnings Call Transcript
Geron Corp (GERN) Q3 2026 Earnings Call Highlights: RYTELO Revenue Climbs 27% as Cost Cuts Lift ...
Geron Corporation Q3 2026 Earnings Call Summary
Geron Q3 Earnings Call Highlights
Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Geron Corporation (GERN) Q3 2026 Earnings Call Transcript
Geron To Present Six Abstracts At 68th American Society Of Hematology Annual Meeting
Geron Q3 2026 Earnings Call Transcript
Geron Corporation to Participate in the Stifel 2026 Healthcare Conference
Geron: Opportunity Builds Even As Struggles Continue
Geron winds down Phase III rare blood cancer trial after muted efficacy
Geron Corporation: IMPACT-MF Study Discontinuation May Not Be So Disastrous
Wedbush Maintains Outperform on Geron, Lowers Price Target to $5
Geron's Core Rytelo Business Remains on Track Despite Trial Halt, Wedbush Says
Needham Maintains Buy on Geron, Lowers Price Target to $2.5
Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.